• Je něco špatně v tomto záznamu ?

Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B

S. Fung, P. Kwan, M. Fabri, A. Horban, M. Pelemis, HW. Hann, S. Gurel, FA. Caruntu, JF. Flaherty, B. Massetto, P. Dinh, A. Corsa, GM. Subramanian, JG. McHutchison, P. Husa, E. Gane,

. 2014 ; 146 (4) : 980-8.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14063788

BACKGROUND & AIMS: Tenofovir disoproxil fumarate (TDF) is active against lamivudine-resistant hepatitis B virus (HBV) infection, but data to support its clinical efficacy in this setting are limited. METHODS: In a prospective, double-blind, 96-week trial, patients were randomly assigned (1:1) to groups given TDF (300 mg, n = 141) or a combination of emtricitabine (FTC, 200 mg; n = 139) and TDF (300 mg, FTC/TDF). Patients were hepatitis B e antigen (HBeAg)-positive or HBeAg-negative, with levels of HBV DNA ≥3 log10 IU/mL and lamivudine resistance mutations (HBV polymerase or reverse transcriptase amino acid substitutions rtM204I/V ± rtL180M by INNO-LiPA Multi-DR v3; Innogenetics, Inc, Alpharetta, GA). The primary end point was proportion with HBV DNA <69 IU/mL (Roche COBAS Taqman assay; Roche Molecular Systems, Inc, Pleasanton, CA). RESULTS: Patient groups were well matched for demographic and disease characteristics, including region (60% from Europe), HBV genotype (45% genotype D), HBeAg status (47% HBeAg-positive), and duration of lamivudine treatment (mean, 3.8 years). At week 96 of treatment, 89.4% of patients in the TDF group and 86.3% in the FTC/TDF group had levels of HBV DNA <69 IU/mL (P = .43). HBeAg loss and seroconversion did not differ between groups; only 1 patient (0.7%) in the FTC/TDF group lost hepatitis B surface antigen. Treatment was well tolerated; confirmed renal events (creatinine increase of ≥0.5 mg/dL [>44 umol/L], creatinine clearance <50 mL/min, or level of PO4 <2 mg/dL [<0.65 mmol/L]) were generally mild and infrequent (<1%). Small reductions (<2%) in mean bone mineral density of hip and spine were detected by dual-energy x-ray absorptiometry in both groups. No TDF resistance developed through 96 weeks of treatment. CONCLUSIONS: TDF alone is safe and effective for treatment of patients with lamivudine-resistant, chronic HBV infection. Clinical Trials.gov No, NCT00737568.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14063788
003      
CZ-PrNML
005      
20140709125135.0
007      
ta
008      
140704s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1053/j.gastro.2013.12.028 $2 doi
035    __
$a (PubMed)24368224
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fung, Scott $u Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: Scott.fung@uhn.on.ca.
245    10
$a Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B / $c S. Fung, P. Kwan, M. Fabri, A. Horban, M. Pelemis, HW. Hann, S. Gurel, FA. Caruntu, JF. Flaherty, B. Massetto, P. Dinh, A. Corsa, GM. Subramanian, JG. McHutchison, P. Husa, E. Gane,
520    9_
$a BACKGROUND & AIMS: Tenofovir disoproxil fumarate (TDF) is active against lamivudine-resistant hepatitis B virus (HBV) infection, but data to support its clinical efficacy in this setting are limited. METHODS: In a prospective, double-blind, 96-week trial, patients were randomly assigned (1:1) to groups given TDF (300 mg, n = 141) or a combination of emtricitabine (FTC, 200 mg; n = 139) and TDF (300 mg, FTC/TDF). Patients were hepatitis B e antigen (HBeAg)-positive or HBeAg-negative, with levels of HBV DNA ≥3 log10 IU/mL and lamivudine resistance mutations (HBV polymerase or reverse transcriptase amino acid substitutions rtM204I/V ± rtL180M by INNO-LiPA Multi-DR v3; Innogenetics, Inc, Alpharetta, GA). The primary end point was proportion with HBV DNA <69 IU/mL (Roche COBAS Taqman assay; Roche Molecular Systems, Inc, Pleasanton, CA). RESULTS: Patient groups were well matched for demographic and disease characteristics, including region (60% from Europe), HBV genotype (45% genotype D), HBeAg status (47% HBeAg-positive), and duration of lamivudine treatment (mean, 3.8 years). At week 96 of treatment, 89.4% of patients in the TDF group and 86.3% in the FTC/TDF group had levels of HBV DNA <69 IU/mL (P = .43). HBeAg loss and seroconversion did not differ between groups; only 1 patient (0.7%) in the FTC/TDF group lost hepatitis B surface antigen. Treatment was well tolerated; confirmed renal events (creatinine increase of ≥0.5 mg/dL [>44 umol/L], creatinine clearance <50 mL/min, or level of PO4 <2 mg/dL [<0.65 mmol/L]) were generally mild and infrequent (<1%). Small reductions (<2%) in mean bone mineral density of hip and spine were detected by dual-energy x-ray absorptiometry in both groups. No TDF resistance developed through 96 weeks of treatment. CONCLUSIONS: TDF alone is safe and effective for treatment of patients with lamivudine-resistant, chronic HBV infection. Clinical Trials.gov No, NCT00737568.
650    _2
$a adenin $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D000225
650    _2
$a dospělí $7 D000328
650    _2
$a antivirové látky $x škodlivé účinky $x terapeutické užití $7 D000998
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a DNA virů $x krev $7 D004279
650    _2
$a deoxycytidin $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D003841
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a fixní kombinace léků $7 D004338
650    12
$a virová léková rezistence $x genetika $7 D024882
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genotyp $7 D005838
650    _2
$a hepatitida B - antigeny e $x krev $7 D006513
650    _2
$a virus hepatitidy B $x účinky léků $x genetika $x imunologie $7 D006515
650    _2
$a chronická hepatitida B $x diagnóza $x farmakoterapie $7 D019694
650    _2
$a lidé $7 D006801
650    _2
$a lamivudin $x škodlivé účinky $x terapeutické užití $7 D019259
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a organofosfonáty $x škodlivé účinky $x terapeutické užití $7 D063065
650    _2
$a prospektivní studie $7 D011446
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a virová nálož $7 D019562
651    _2
$a Evropa $7 D005060
651    _2
$a Nový Zéland $7 D009520
651    _2
$a Severní Amerika $7 D009656
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kwan, Peter $u University of British Columbia, Vancouver, British Columbia, Canada.
700    1_
$a Fabri, Milotka $u Clinic for Infectious Diseases, Medical University of Novi Sad, Serbia.
700    1_
$a Horban, Andrzej $u Medical University of Warsaw, Warsaw, Poland.
700    1_
$a Pelemis, Mijomir $u Clinic for Infectious and Tropical Diseases, Clinical Center of Serbia, Belgrade Medical Faculty, Belgrade, Serbia.
700    1_
$a Hann, Hie-Won $u Thomas Jefferson University, Philadelphia, Pennsylvania.
700    1_
$a Gurel, Selim $u Uludag Universitesi Tip Fakultesi, Bursa, Gorukle, Turkey.
700    1_
$a Caruntu, Florin A $u National Institute for Infectious Diseases, "Prof Dr Matei Bals," Bucharest, Romania.
700    1_
$a Flaherty, John F $u Gilead Sciences, Inc, Foster City, California.
700    1_
$a Massetto, Benedetta $u Gilead Sciences, Inc, Foster City, California.
700    1_
$a Dinh, Phillip $u Gilead Sciences, Inc, Foster City, California.
700    1_
$a Corsa, Amoreena $u Gilead Sciences, Inc, Foster City, California.
700    1_
$a Subramanian, G Mani $u Gilead Sciences, Inc, Foster City, California.
700    1_
$a McHutchison, John G $u Gilead Sciences, Inc, Foster City, California.
700    1_
$a Husa, Petr $u University Hospital Brno and Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic.
700    1_
$a Gane, Edward $u Auckland City Hospital, Auckland, New Zealand.
773    0_
$w MED00001877 $t Gastroenterology $x 1528-0012 $g Roč. 146, č. 4 (2014), s. 980-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24368224 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140704 $b ABA008
991    __
$a 20140709125427 $b ABA008
999    __
$a ok $b bmc $g 1031272 $s 862520
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 146 $c 4 $d 980-8 $i 1528-0012 $m Gastroenterology $n Gastroenterology $x MED00001877
LZP    __
$a Pubmed-20140704

Najít záznam

Citační ukazatele

Možnosti archivace